In the present study, we assess the feasibility of lentiviral vector-delivered small hairpin RNA (shRNA) against ADAM9 for the treatment of androgen-independent and bone metastatic human prostate cancer in an experimental animal model. The gene discussed is ADAM9; the disease is prostate cancer.